Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 14, 2024

BUY
$222.59 - $267.94 $2.32 Million - $2.8 Million
10,444 Added 43.06%
34,696 $8.98 Million
Q3 2023

Nov 14, 2023

SELL
$253.3 - $285.89 $1.91 Million - $2.15 Million
-7,525 Reduced 23.68%
24,252 $6.23 Million
Q2 2023

Aug 14, 2023

SELL
$275.25 - $318.06 $3.13 Million - $3.61 Million
-11,355 Reduced 26.33%
31,777 $9.05 Million
Q1 2023

May 15, 2023

BUY
$256.56 - $292.34 $3.54 Million - $4.04 Million
13,806 Added 47.08%
43,132 $12 Million
Q4 2022

Feb 14, 2023

BUY
$252.44 - $306.72 $4.11 Million - $4.99 Million
16,266 Added 124.55%
29,326 $8.12 Million
Q3 2022

Nov 14, 2022

BUY
$194.69 - $268.46 $625,344 - $862,293
3,212 Added 32.62%
13,060 $3.49 Million
Q2 2022

Aug 15, 2022

BUY
$187.54 - $223.02 $1.85 Million - $2.2 Million
9,848 New
9,848 $2.01 Million
Q2 2019

Aug 14, 2019

SELL
$219.29 - $241.72 $1.54 Million - $1.69 Million
-7,000 Closed
0 $0
Q1 2019

May 15, 2019

SELL
$216.71 - $338.96 $1.52 Million - $2.37 Million
-7,000 Reduced 50.0%
7,000 $1.66 Million
Q4 2018

Feb 14, 2019

SELL
$278.5 - $352.75 $207,761 - $263,151
-746 Reduced 5.06%
14,000 $4.21 Million
Q3 2018

Nov 14, 2018

BUY
$293.51 - $383.83 $1.39 Million - $1.82 Million
4,746 Added 47.46%
14,746 $5.21 Million
Q2 2018

Aug 14, 2018

BUY
$257.52 - $306.91 $257,519 - $306,910
1,000 Added 11.11%
10,000 $2.9 Million
Q1 2018

May 15, 2018

BUY
$260.13 - $367.91 $1.56 Million - $2.21 Million
6,000 Added 200.0%
9,000 $2.46 Million
Q4 2017

Feb 14, 2018

SELL
$307.64 - $344.58 $8.31 Million - $9.3 Million
-27,000 Reduced 90.0%
3,000 $956,000
Q3 2017

Nov 14, 2017

BUY
$281.15 - $329.69 $8.43 Million - $9.89 Million
30,000
30,000 $9.39 Million

Others Institutions Holding BIIB

About BIOGEN INC.


  • Ticker BIIB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 144,000,992
  • Market Cap $21.1B
  • Description
  • Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...
More about BIIB
Track This Portfolio

Track Weiss Multi Strategy Advisers LLC Portfolio

Follow Weiss Multi Strategy Advisers LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Weiss Multi Strategy Advisers LLC, based on Form 13F filings with the SEC.

News

Stay updated on Weiss Multi Strategy Advisers LLC with notifications on news.